 Because each cancer is unique, the vaccine is derived from the patient's own tumor sample.To process these samples, Agenus has established a multi-product Good Manufacturing Practices (GMP) facility, which has already helped process over 1,000 tumor samples from across the globe.The company's QS-21 Stimulon® adjuvant platform strengthens and broadens immune responses to antigens on cancers or foreign invaders’ surfaces.